Loading...
Market
How many new PBC patients will start treatment with Livdelzi by August 14, 2025?
2
Resolution / Starting Odds
Less than 5,000 • 25%
5,000 to 10,000 • 25%
10,000 to 15,000 • 25%
More than 15,000 • 25%
Gilead's annual report or press releases
Story
FDA Approves Gilead's $4.3B Acquisition Drug Livdelzi for PBC
Aug 14, 2024, 07:23 PM
The U.S. Food and Drug Administration (FDA) has granted accelerated approval to Gilead Sciences' drug Livdelzi (Seladelpar) for the treatment of primary biliary cholangitis (PBC), an autoimmune liver disease that primarily affects women. This approval follows Gilead's acquisition of CymaBay Therapeutics for $4.3 billion earlier this year. The treatment, which is used in combination with ursodeoxycholic acid, demonstrated significant improvements in liver disease markers and pruritus. The approval is based on data from the Phase 3 RESPONSE study and marks Gilead's first launch of an inflammatory drug.
View original story
Similar markets
Less than 10 • 25%
10-20 • 25%
20-30 • 25%
More than 30 • 25%
Less than 100 • 25%
100 - 500 • 25%
500 - 1000 • 25%
More than 1000 • 25%
Less than 10% • 25%
10-20% • 25%
20-30% • 25%
More than 30% • 25%
Less than 100 • 33%
100 to 500 • 34%
More than 500 • 33%
Less than 50,000 • 25%
50,000 to 75,000 • 25%
75,000 to 100,000 • 25%
More than 100,000 • 25%
Yes • 50%
No • 50%
Less than 500 • 25%
500-1000 • 25%
1001-2000 • 25%
More than 2000 • 25%
FDA approval granted • 25%
FDA approval denied • 25%
Further trials required • 25%
Withdrawn by Gilead • 25%
Less than 100 • 25%
100 to 200 • 25%
201 to 300 • 25%
More than 300 • 25%
Less than 5,000 • 25%
5,000 - 10,000 • 25%
10,000 - 15,000 • 25%
More than 15,000 • 25%